Kratom and 7-OH Before Rehab: What Intake Needs

, , ,
Admissions

Kratom is easy to leave off a rehab intake form. It is sold in smoke shops and gas stations, the package often calls it a botanical or a supplement, and many people started taking it to ease opioid withdrawal or pain rather than to get high. For someone entering residential treatment for a substance use disorder, though, kratom and especially the concentrated 7-OH products now sold alongside it change how the first days of care are planned. This guide explains what intake needs to know, what changed in federal rules in 2026, and a label check you can do before you call. If you would rather talk it through now, our admissions team is at (855) 778-8668.

The short answer

Kratom (Mitragyna speciosa) is a Southeast Asian plant whose compounds mitragynine and 7-hydroxymitragynine (7-OH) act on the same mu-opioid receptors as prescription opioids. According to the FDA, 7-OH makes up less than 2% of the total alkaloid content of natural kratom leaf, yet many products now sold as kratom are concentrated 7-OH tablets, shots or gummies with far stronger opioid activity. For anyone entering residential addiction treatment, that difference matters more than the word on the package: intake needs the product name, the milligrams of 7-OH per serving if listed, servings per day, the time of the last dose, and whether alcohol, opioids or benzodiazepines are also being used.

Why kratom leaf and 7-OH are not the same exposure

The National Institute on Drug Abuse estimates that about 1.7 million people aged 12 or older used kratom in 2021, and it notes that there are no FDA-approved medical uses for kratom. NIDA also describes the evidence carefully: studies suggest people who stop regular kratom use may have mild to moderate withdrawal, and deaths from kratom alone appear to be rare, with nearly all reported deaths involving other drugs or contaminants. The risk picture shifts when the product, the dose or the company changes. These are the mechanisms intake staff are thinking about:

Concentrated 7-OH: The FDA states that 7-OH has substantially greater mu-opioid receptor potency than mitragynine and than morphine, so a 7-OH product behaves more like an opioid than a leaf powder does.

Slowed breathing: NIDA reports that in laboratory models 7-OH can cause respiratory depression that naloxone reverses, which is the same overdose pattern seen with other opioids.

Combined sedation: Kratom taken with alcohol, benzodiazepines, opioids or other sedating medications adds to their effects, and case reports link this kind of polysubstance use to severe outcomes.

Product variability: Kratom products are not standardized, and some have been found to contain contaminants such as heavy metals or bacteria, so two bags with the same name may not contain the same thing.

Self-treatment of opioid withdrawal: Many people use kratom to manage opioid cravings or withdrawal, which means stopping kratom can uncover an opioid use disorder that was being covered rather than treated.

What changed in federal rules in 2026

Kratom itself is not on the federal schedule of controlled substances, and the DEA lists it as a drug of concern. The rules for 7-OH and related compounds have been moving quickly this year. According to the FDA’s 7-OH products page, last updated 12 October 2026, the DEA temporarily placed three related compounds (MGPI, MGM-15 and MGM-16) into Schedule I on 26 August 2026. On 9 October 2026 the DEA issued notices of intent based on an HHS recommendation that 7-OH and MGPI be Schedule I when a product contains more than 1 milligram per gram (solid) or 1 milligram per milliliter (liquid), or when the ratio of mitragynine to 7-OH is less than 100 to 1.

Two practical points follow. First, that line is a regulatory threshold designed to separate enhanced products from leaf-like ones; it is not a clinical safe dose. Second, the status was still a proposal when that page was updated, so products bought earlier this year may now be in a different legal category. None of this changes how a treatment team responds. Intake is not a legal review, and what you disclose is used to plan care safely.

A label check you can do today

Before you call admissions, gather every kratom or 7-OH product in the house, including empty packaging, and take a clear photo of each label. Then write down four things for each one:

Product form: leaf powder or capsules, liquid extract or shot, or a tablet or gummy marketed as 7-OH.

Milligrams listed: the mitragynine and 7-OH per serving, if the label states them. If 7-OH is listed at all, or the label shows less than 100 times as much mitragynine as 7-OH, tell intake plainly that this is a concentrated product.

Real daily amount: how many servings are actually taken in a day, not what the package suggests, and whether that number has gone up over the past month.

Last dose: the date and clock time of the most recent dose, and the plan between now and admission.

Bring the photos to the admissions call. A picture of the label answers questions that memory often cannot, and it lets the medical team compare what was taken with what the package claims. Do not stop suddenly on your own before admission if you are also drinking daily or taking benzodiazepines; ask the team how to handle the days before you arrive. Our page on last drink and last dose timing explains why that timing matters.

Why a drug screen may not show it

Standard urine drug screens used in many clinics and workplaces are not designed to detect mitragynine or 7-OH. Specialized testing exists, but it is not part of every routine panel. In practice that means a negative screen does not rule out kratom use, and the treatment team relies on what the person reports, the product labels and the medication history. Leaving kratom off the form does not make it invisible to the body; it only makes it invisible to the people planning the first nights of care.

How the medical team plans withdrawal

NIDA notes that there are currently no FDA-approved treatments specifically for kratom-related withdrawal, and that some clinicians have reported using medications in limited cases. In a supervised setting, a physician decides how to manage symptoms based on the product, the daily amount, other substances in use and the person’s health. When kratom has been used to manage opioid withdrawal, the team may assess for opioid use disorder and discuss options such as buprenorphine treatment; that decision belongs to the prescriber, not to a label or a website.

Alcohol and benzodiazepine withdrawal carry a risk of seizures, and medical supervision is required when either is part of the picture. If kratom is one of several substances in use, medically supervised detox is the safer path than stopping everything at home. Because 7-OH acts like an opioid, anyone using it should also have naloxone available; NIDA’s naloxone guidance explains how it works.

When kratom was covering something else

NIDA reports that people often use kratom to self-manage pain, fatigue, anxiety or depression, and many report more than one reason. In residential care, those conditions are treated as co-occurring alongside the substance use disorder, not set aside. A person who has used kratom for chronic pain or anxiety while also struggling with opioids or alcohol may need a dual diagnosis assessment so that both the substance use and the co-occurring condition have a plan before kratom is taken away. Questions worth asking at intake include: what will be used for pain during withdrawal, who adjusts psychiatric medications, and how sleep will be supported in the first week. Our page on kratom rehab in Los Angeles describes how this works at Annandale’s small six-bed residence in Pasadena.

Signs of an emergency

Call 911 if someone using kratom or 7-OH is hard to wake, breathing slowly or not at all, has blue or gray lips, or has a seizure. Give naloxone if opioid overdose is possible and you have it. For questions about a possible poisoning, Poison Control is at 1-800-222-1222. If someone is in emotional crisis or thinking about suicide, call or text 988. For free, confidential treatment referrals at any hour, the SAMHSA National Helpline is 1-800-662-4357.

Talk to us about kratom and 7-OH

You do not need to know the exact numbers before you call. Bring what you have, the labels, the last dose time and an honest daily amount, and the admissions team will help with the rest. Annandale Behavioral Health is a DHCS-licensed residential program for substance use disorders and co-occurring conditions in Pasadena. Call (855) 778-8668 to talk through whether residential care is the right fit.

This article is for educational purposes only and is not medical advice. Kratom and 7-OH regulations were changing at the time of writing; check current federal and local rules. Do not change or stop any medication or substance without talking to a qualified healthcare provider, and call 911 in an emergency.